Adding an acetazolamide-type drug to lung cancer radiation and drugs
Part of Cancer, Lungs & breathing clinical trials.
This Phase 1 trial tests whether blocking an enzyme (with an acetazolamide-like medicine) can be safely combined with standard treatment for small cell lung cancer that has not spread. The goal is to see if the treatment can be given safely and to learn early signs of benefit.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You have small cell lung cancer that has not spread to other organs (metastatic disease is not allowed)
- You must be able to start a specific treatment plan: either radiation plus chemotherapy with platinum and etoposide, or (for extensive disease) specific chemo-immunotherapy cycles
- Your health status is fairly good (performance status 0 to 2)
- Your scans show measurable tumor changes that can be followed (RECIST and/or PERCIST criteria)
- You can safely use contraception to prevent pregnancy during the study and for 1 month after, and you can complete required pregnancy testing if you can get pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy, immunotherapy, and targeted radiation for people with extensive-stage small-cell lung cancer. The goal is to see if adding radiation to leftover tumors after initial treatment helps control the disease better.
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
This trial tests a new drug (tarlatamab) combined with chemotherapy and immunotherapy for people whose lung cancer has changed from one type (adenocarcinoma) to small cell lung cancer after treatment with EGFR targeted therapy. The goal is to see if this combination is safe and works well.
This trial combines radiation therapy with chemotherapy and an immunotherapy drug to treat limited-stage small cell lung cancer. The goal is to see if this approach helps people live longer and delays the cancer from coming back.
This trial tests a combination of low-dose radiation to the chest, immunotherapy (adebrelimab), and chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this approach can help control the cancer better than standard treatments and potentially improve outcomes.
This trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps people with extensive-stage small cell lung cancer. It is for those who have not had treatment for this stage yet.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.